☰

Steven P. Rowe, Ph.D. - Publications

Affiliations: 
2009 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Chemical biology
Tree Info Similar researchers PubMed Report error

138 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Dong L, Zhu Y, Xin M, Dong B, Pan J, Liu J, Amend SR, Xue W, Pienta KJ, Rowe SP. Prospective evaluation of Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level. Medical Oncology (Northwood, London, England). 37: 89. PMID 32920666 DOI: 10.1007/S12032-020-01412-7  0.353
2020 Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, Schulz S, Higuchi T, Buck AK, Bengel FM, Bundschuh RA, Lapa C. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32859702 DOI: 10.2967/Jnumed.120.245464  0.316
2020 Wright WF, Auwaerter PG, Dibble EH, Rowe SP, Mackowiak PA. Imaging a Fever - Redefining the role of 18FDG-PET/CT in FUO Investigations. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32829386 DOI: 10.1093/Cid/Ciaa1220  0.352
2020 Sheikhbahaei S, Verde F, Hales RK, Rowe SP, Solnes LB. Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of F-FDG PET/CT. Clinical Lung Cancer. PMID 32723523 DOI: 10.1016/J.Cllc.2020.06.020  0.343
2020 Zukotynski KA, Rowe SP. Histologic Validation of F-DCFPyL PET/CT with Comparison to Multiparametric MRI in Biochemically Recurrent Prostate Cancer. Radiology. 202098. PMID 32639193 DOI: 10.1148/Radiol.2020202098  0.362
2020 Reyes DK, Rowe SP, Schaeffer EM, Allaf ME, Ross AE, Pavlovich CP, Deville C, Tran PT, Pienta KJ. Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Medical Oncology (Northwood, London, England). 37: 60. PMID 32524295 DOI: 10.1007/S12032-020-01385-7  0.322
2020 Rowe SP, Gorin MA, Pomper MG. Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating. Translational Andrology and Urology. 9: 840-842. PMID 32420196 DOI: 10.21037/Tau.2020.01.27  0.306
2020 Rowe SP, Johnson GB, Pomper MG, Gorin MA, Behr SC. Recent updates and developments in PET imaging of prostate cancer. Abdominal Radiology (New York). PMID 32417934 DOI: 10.1007/S00261-020-02570-Y  0.384
2020 Hrinivich WT, Phillips R, Da Silva AJ, Radwan N, Gorin MA, Rowe SP, Pienta KJ, Pomper MG, Wong J, Tran PT, Kang-Hsin Wang K. Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. Advances in Radiation Oncology. 5: 260-268. PMID 32280826 DOI: 10.1016/J.Adro.2019.10.006  0.339
2020 Markowski MC, Sedhom R, Fu W, Gray JCR, Eisenberger MA, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. PSA and PSA Doubling Time Predict Findings on F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32250727 DOI: 10.1097/Ju.0000000000001064  0.367
2020 Ruiz-Bedoya CA, Ordonez AA, Werner RA, Plyku D, Klunk MH, Leal J, Lesniak WG, Holt DP, Dannals RF, Higuchi T, Rowe SP, Jain SK. C-PABA as a Novel PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Studies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32198314 DOI: 10.2967/Jnumed.119.239806  0.3
2020 Su ZT, Patel HD, Huang MM, Meyer AR, Pavlovich CP, Pierorazio PM, Javadi MS, Allaf ME, Rowe SP, Gorin MA. Cost-effectiveness Analysis of Tc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. European Urology Focus. PMID 32115400 DOI: 10.1016/J.Euf.2020.02.010  0.308
2020 Ordonez AA, Wang H, Magombedze G, Ruiz-Bedoya CA, Srivastava S, Chen A, Tucker EW, Urbanowski ME, Pieterse L, Fabian Cardozo E, Lodge MA, Shah MR, Holt DP, Mathews WB, Dannals RF, ... ... Rowe SP, et al. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. Nature Medicine. PMID 32066976 DOI: 10.1038/S41591-020-0770-2  0.308
2020 Liu C, Liu T, Zhang Z, Zhang N, Du P, Yang Y, Liu Y, Yu W, Li N, Gorin MA, Rowe SP, Zhu H, Yan K, Yang Z. PSMA PET/CT and standard plus PET/CT-Ultrasound fusion targeted prostate biopsy can diagnose clinically significant prostate cancer in men with previous negative biopsies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32034111 DOI: 10.2967/Jnumed.119.235333  0.376
2020 Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP. F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. 10: 1-16. PMID 31903102 DOI: 10.7150/Thno.37894  0.384
2020 Pouliot F, Carroll P, Probst S, Pienta KJ, Rowe SP, Saperstein L, Siegel B, Patnaik A, Preston MA, Alva AS, Gorin MA, Morris MJ. A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. Journal of Clinical Oncology. 38: 9-9. DOI: 10.1200/Jco.2020.38.6_Suppl.9  0.386
2020 Meyer A, Stambler N, Sjostrand K, Richter J, Allaf M, Rowe S, Wong V, Anand A, Gorin M. Pd57-06 Deep Learning Algorithm Improves Identification Of Men With Low Risk Prostate Cancer Using Psma-Targeted 99Mtc-Mip-1404 Spect/Ct The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000967.06  0.305
2020 Gorin MA, Siegel BA, Rowe SP, Saperstein L, Pouliot F, Josephson DY, Wong JYC, Pantel AR, Cho S, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, et al. Lba02-12 A Multicenter Phase 3 Study Of Psma-Targeted 18F-Dcfpyl Pet/Ct In Men With Biochemically Recurrent Prostate Cancer: Results From The Condor Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000958.012  0.367
2020 Sprenkle P, Carroll P, Probst S, Gorin MA, Rowe SP, Pienta KJ, Pouliot F, Patnaik A, Preston MA, Alva A, Siegel BA, Morris MJ. Pd38-05 Clinical Utility Of Preoperative Psma-Targeted 18F-Dcfpyl Pet/Ct In Men With High-Risk Prostate Cancer: Diagnostic Performance Comparisons With Pelvic Ct Or Mri In The Osprey Prospective, Multi-Center Trial The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000917.05  0.362
2019 Meyer AR, Leroy A, Allaf ME, Rowe SP, Gorin MA. Incidentally Detected F-FDG-Avid Prostate Cancer Diagnosed Using a Novel Fusion Biopsy Platform. Journal of Endourology Case Reports. 5: 68-70. PMID 32760804 DOI: 10.1089/Cren.2019.0008  0.374
2019 Yin Y, Paller CJ, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. World Journal of Nuclear Medicine. 18: 424-427. PMID 31933562 DOI: 10.4103/Wjnm.Wjnm_50_18  0.394
2019 Torga G, Yin Y, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. Uptake of prostate-specific membrane antigen-targeted F-DCFPyL in avascular necrosis of the femoral head. World Journal of Nuclear Medicine. 18: 416-419. PMID 31933560 DOI: 10.4103/Wjnm.Wjnm_106_18  0.407
2019 Werner RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP, Lodge MA, Bundschuh RA. Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake". Molecular Imaging and Biology. PMID 31832870 DOI: 10.1007/S11307-019-01452-0  0.332
2019 Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, Buck AK, Pomper MG, Rowe SP, Lapa C. CXCR4-Directed Imaging in Solid Tumors. Frontiers in Oncology. 9: 770. PMID 31475113 DOI: 10.3389/Fonc.2019.00770  0.347
2019 Rowe SP, Li X, Trock BJ, Werner RA, Frey SM, DiGianvittorio M, Bleiler K, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG. Prospective Comparison of PET Imaging with PSMA-targeted F-DCFPyL versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31451492 DOI: 10.2967/Jnumed.119.227793  0.373
2019 Batra JS, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications? Translational Andrology and Urology. 8: S263-S264. PMID 31392140 DOI: 10.21037/Tau.2019.03.13  0.319
2019 Rowe SP, Solnes LB, Yin Y, Kitchen G, Lodge MA, Karakatsanis NA, Rahmim A, Pomper MG, Leal JP. Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. Journal of Digital Imaging. PMID 31388864 DOI: 10.1007/S10278-019-00255-7  0.312
2019 Rowe SP, Chu LC, Meyer AR, Gorin MA, Fishman EK. The application of cinematic rendering to CT evaluation of upper tract urothelial tumors: principles and practice. Abdominal Radiology (New York). PMID 31367896 DOI: 10.1007/S00261-019-02154-5  0.31
2019 Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate. PMID 31361358 DOI: 10.1002/Pros.23883  0.318
2019 Werner RA, Lapa C, Sheikhbahaei S, Marcus C, Solnes LB, Du Y, Leal JP, Buck AK, Higuchi T, Rowe SP, Javadi MS. Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [123I]Ioflupane single photon emission computed tomography/computed tomography. Nuclear Medicine Communications. PMID 31343608 DOI: 10.1097/Mnm.0000000000001061  0.319
2019 Chen X, Fritz A, Werner RA, Nose N, Yagi Y, Kimura H, Rowe SP, Koshino K, Decker M, Higuchi T. Initial Evaluation of AF78: a Rationally Designed Fluorine-18-Labelled PET Radiotracer Targeting Norepinephrine Transporter. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31332629 DOI: 10.1007/S11307-019-01407-5  0.306
2019 Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. Journal of Clinical Medicine. 8. PMID 31331016 DOI: 10.3390/Jcm8071060  0.394
2019 Werner RA, Koshino K, Arimitsu K, Lapa C, Javadi MS, Rowe SP, Nose N, Kimura H, Fukushima K, Higuchi T. Stability of Distribution of F18 Flurpiridaz After Transient Coronary Occlusion in Pigs. Jacc. Cardiovascular Imaging. PMID 31326498 DOI: 10.1016/J.Jcmg.2019.05.018  0.329
2019 Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C, Schirbel A, Rowe SP, Pomper MG, Buck AK, Wester HJ, Ernestus RI, Lapa C. [Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. Frontiers in Oncology. 9: 503. PMID 31245296 DOI: 10.3389/Fonc.2019.00503  0.328
2019 Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine. 49: 255-270. PMID 31227049 DOI: 10.1053/J.Semnuclmed.2019.02.006  0.375
2019 Meyer AR, Rowe SP, Gorin MA. Preoperative PSMA-targeted PET imaging: more than just a tool for prostate cancer staging? Bju International. 124: 2-3. PMID 31207000 DOI: 10.1111/Bju.14624  0.366
2019 Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA. Prospective Evaluation of PSMA-Targeted F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31201249 DOI: 10.2967/Jnumed.119.226514  0.386
2019 Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf ME, Rowe SP, Gorin MA. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. Annals of Nuclear Medicine. PMID 31147927 DOI: 10.1007/S12149-019-01371-8  0.348
2019 Werner RA, Chen X, Lapa C, Koshino K, Rowe SP, Pomper MG, Javadi MS, Higuchi T. The next era of renal radionuclide imaging: novel PET radiotracers. European Journal of Nuclear Medicine and Molecular Imaging. PMID 31144061 DOI: 10.1007/S00259-019-04359-8  0.347
2019 Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31140110 DOI: 10.1007/S11307-019-01375-W  0.347
2019 Werner RA, Savoie B, Javadi MS, Pomper MG, Higuchi T, Lapa C, Rowe SP. From the Reading Room to the Courtroom-The Use of Molecular Radionuclide Imaging in Criminal Trials. Journal of the American College of Radiology : Jacr. PMID 31132333 DOI: 10.1016/J.Jacr.2019.05.001  0.322
2019 Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31115751 DOI: 10.1007/S11307-019-01376-9  0.38
2019 Rowe SP, Chu LC, Fishman EK. Computed Tomography Cinematic Rendering in the Evaluation of Colonic Pathology: Technique and Clinical Applications. Journal of Computer Assisted Tomography. 43: 475-484. PMID 31082955 DOI: 10.1097/Rct.0000000000000864  0.313
2019 Sheikhbahaei S, Jones KM, Werner RA, Salas-Fragomeni RA, Marcus CV, Higuchi T, Rowe SP, Solnes LB, Javadi MS. F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine. PMID 30877561 DOI: 10.1007/S12149-019-01343-Y  0.362
2019 Werner RA, Chen X, Rowe SP, Lapa C, Javadi MS, Higuchi T. Recent paradigm shifts in molecular cardiac imaging-Establishing precision cardiology through novel F-labeled PET radiotracers. Trends in Cardiovascular Medicine. PMID 30824163 DOI: 10.1016/J.Tcm.2019.02.007  0.33
2019 Werner RA, Bundschuh R, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP. Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30796171 DOI: 10.2967/Jnumed.118.223537  0.35
2019 Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine. PMID 30789396 DOI: 10.1097/Rlu.0000000000002489  0.378
2019 Werner RA, Ordonez AA, Sanchez-Bautista J, Marcus C, Lapa C, Rowe SP, Pomper MG, Leal JP, Lodge MA, Javadi MS, Jain SK, Higuchi T. Novel Functional Renal PET Imaging With 18F-FDS in Human Subjects. Clinical Nuclear Medicine. PMID 30762825 DOI: 10.1097/Rlu.0000000000002494  0.321
2019 Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, Pienta KJ. PSMA-targeted [F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urology Case Reports. 23: 72-74. PMID 30705827 DOI: 10.1016/J.Eucr.2019.01.007  0.347
2019 Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annual Review of Medicine. 70: 461-477. PMID 30691373 DOI: 10.1146/Annurev-Med-062117-073027  0.414
2019 Morris MJ, Pouliot F, Saperstein L, Rowe SP, Gorin MA, Josephson DY, Wong JYC, Carroll P, Lin T, Stambler N, Wong V, Jensen JD, Siegel BA. A phase III, multicenter study to assess the diagnostic performance and clinical impact of 18F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps5093  0.365
2019 Meyer A, Stambler N, Sjöstrand K, Richter J, Allaf M, Rowe SP, Wong V, Anand A, Gorin MA. Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted 99mTc-MIP-1404 SPECT/CT. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E16572  0.325
2019 Morris MJ, Durack JC, Alva AS, Vargas HA, Piert M, Pachynski RK, Pouliot F, Beauregard J, Preston MA, Choudhury AD, Saperstein L, Carroll P, Rowe SP, Pienta KJ, Lin T, et al. Diagnostic performance of 18F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC). Journal of Clinical Oncology. 37: 5012-5012. DOI: 10.1200/Jco.2019.37.15_Suppl.5012  0.371
2019 Gorin* MA, Pienta KJ, Siegel BA, Carroll P, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Rowe SP, Nichols M, Lin T, Strack T, et al. PD60-10 A PROSPECTIVE PHASE 2/3 MULTI-CENTER STUDY OF 18 F-DCFPYL PET/CT IMAGING IN PATIENTS WITH PROSTATE CANCER – EXAMINATION OF DIAGNOSTIC ACCURACY (OSPREY) Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557215.99831.87  0.372
2019 Coughlin J, Du Y, Rowe S, Horti A, Pomper M. 14.3 OPPORTUNITIES IN PRECISION PSYCHIATRY USING PET-BASED NEUROIMAGING Schizophrenia Bulletin. 45: S111-S112. DOI: 10.1093/Schbul/Sbz022.056  0.307
2018 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics. 8: 6088-6100. PMID 30613284 DOI: 10.7150/Thno.30357  0.316
2018 Werner RA, Chen X, Rowe SP, Lapa C, Javadi MS, Higuchi T. Moving into the next era of PET myocardial perfusion imaging: introduction of novel F-labeled tracers. The International Journal of Cardiovascular Imaging. PMID 30334228 DOI: 10.1007/S10554-018-1469-Z  0.341
2018 Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. Clinical Nuclear Medicine. PMID 30247210 DOI: 10.1097/Rlu.0000000000002280  0.377
2018 Yin Y, Campbell SP, Markowski MC, Pierorazio PM, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [F]DCFPyL PET/CT. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30218388 DOI: 10.1007/S11307-018-1271-2  0.373
2018 Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, Lapa C. Volumetric and texture analysis of pretherapeutic F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine. PMID 30206772 DOI: 10.1007/S12020-018-1749-3  0.314
2018 Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30190304 DOI: 10.2967/Jnumed.118.217588  0.359
2018 Meyer AR, Joice GA, Allaf ME, Rowe SP, Gorin MA. Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. Current Opinion in Urology. PMID 30188333 DOI: 10.1097/Mou.0000000000000549  0.363
2018 Werner RA, Chen X, Hirano M, Rowe SP, Lapa C, Javadi MS, Higuchi T. SPECT vs. PET in cardiac innervation imaging: clash of the titans. Clinical and Translational Imaging. 6: 293-303. PMID 30148120 DOI: 10.1007/S40336-018-0289-4  0.314
2018 Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine. PMID 30109562 DOI: 10.1007/S12149-018-1291-7  0.401
2018 Azadi J, Nguyen ML, Leroy A, Macura KJ, Gorin MA, Rowe SP. The emerging role of imaging in prostate cancer secondary screening: multiparametric magnetic resonance imaging and the incipient incorporation of molecular imaging. The British Journal of Radiology. 20170960. PMID 30048145 DOI: 10.1259/Bjr.20170960  0.348
2018 Hope TA, Afshar-Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. Ajr. American Journal of Roentgenology. 1-9. PMID 29949419 DOI: 10.2214/Ajr.18.19957  0.357
2018 Rowe SP, Meyer AR, Gorin MA, Johnson PT, Fishman EK. 3D CT of renal pathology: initial experience with cinematic rendering. Abdominal Radiology (New York). PMID 29779157 DOI: 10.1007/S00261-018-1644-7  0.312
2018 Werner RA, Solnes L, Javadi M, Weich A, Gorin M, Pienta K, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29572257 DOI: 10.2967/Jnumed.117.206631  0.324
2018 Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes L, Kiess A, Allaf ME, Pomper M, Gorin MA, Rowe SP. Imaging of Non-Prostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29545375 DOI: 10.2967/Jnumed.117.203570  0.337
2018 Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP. Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. Urology Case Reports. 17: 22-25. PMID 29541580 DOI: 10.1016/J.Eucr.2017.12.011  0.392
2018 Rowe SP, Gorin MA, Allaf ME, Johnson PT, Fishman EK. Photorealistic 3D Cinematic Rendering of Clear Cell Renal Cell Carcinoma From Volumetric CT Data. Urology. PMID 29499261 DOI: 10.1016/J.Urology.2018.02.011  0.309
2018 Plyku D, Mena E, Rowe SP, Lodge MA, Szabo Z, Cho SY, Pomper MG, Sgouros G, Hobbs RF. Combined model-based and patient-specific dosimetry forF-DCFPyL, a PSMA-targeted PET agent. European Journal of Nuclear Medicine and Molecular Imaging. PMID 29460025 DOI: 10.1007/S00259-018-3939-X  0.378
2018 Rowe SP, Pomper MG, Gorin MA. Molecular Imaging of Prostate Cancer: Choosing the Right Agent. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29371403 DOI: 10.2967/Jnumed.117.206318  0.317
2018 Zukotynski KA, Valliant J, Bénard F, Rowe SP, Kim CK, Pomper MG, Cho SY. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. Clinical Nuclear Medicine. PMID 29356735 DOI: 10.1097/Rlu.0000000000001966  0.371
2018 Phillips RM, Gorin MA, Rowe SP, Pomper MG, Pienta KJ, Ross AE, Tran PT. Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urology Case Reports. 16: 86-88. PMID 29226093 DOI: 10.1016/J.Eucr.2017.11.021  0.349
2018 Kiess A, Bishop J, Kang H, Rowe S, Shen C, Brummet M, Eisele D, Rodriguez MB, Ha P, Pomper M. Clinical PET/CT Imaging and Histopathology Demonstrate Expression of Prostate-Specific Membrane Antigen in Salivary Gland Adenoid Cystic Carcinomas International Journal of Radiation Oncology*Biology*Physics. 100: 1381. DOI: 10.1016/J.Ijrobp.2017.12.191  0.363
2017 Werner R, Wakabayashi H, Chen X, Hirano M, Shinaji T, Lapa C, Rowe SP, Javadi MS, Higuchi T. Novel functional renal imaging with 18F-FDS PET in rat models of kidney diseases. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29242399 DOI: 10.2967/Jnumed.117.203828  0.318
2017 Jones KM, Solnes LB, Rowe SP, Gorin MA, Sheikhbahaei S, Fung G, Frey EC, Allaf ME, Du Y, Javadi MS. Use of quantitative SPECT/CT reconstruction in 99mTc-sestamibi imaging of patients with renal masses. Annals of Nuclear Medicine. PMID 29214562 DOI: 10.1007/S12149-017-1222-Z  0.323
2017 Almassi N, Gorin MA, Purysko A, Rowe SP, Kaouk J, Allaf ME, Campbell SC, Rhee A. Use of 99mTc-Sestamibi SPECT/CT in the Diagnosis of Hybrid Oncocytic/Chromophobe Tumor in a Pediatric Patient. Urology. PMID 29174943 DOI: 10.1016/J.Urology.2017.11.015  0.312
2017 Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. European Urology. PMID 29132714 DOI: 10.1016/J.Eururo.2017.10.027  0.385
2017 Ambinder EB, Rowe SP. A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. Clinical Nuclear Medicine. PMID 29076897 DOI: 10.1097/Rlu.0000000000001859  0.307
2017 Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET/CT for imaging urothelial carcinoma. Annals of Nuclear Medicine. PMID 29067547 DOI: 10.1007/S12149-017-1216-X  0.352
2017 Gorin MA, Rowe SP. Kidney cancer: PSMA: a potential therapeutic target in RCC. Nature Reviews. Urology. PMID 29039420 DOI: 10.1038/Nrurol.2017.164  0.361
2017 Rowe SP, Javadi MS, Solnes LB, Fishman EK. Appearance of Adrenal Myelolipomas on 2-deoxy-2-((18)F) fluoro-D-glucose Positron Emission Tomography-Computed Tomography. World Journal of Nuclear Medicine. 16: 271-274. PMID 29033674 DOI: 10.4103/1450-1147.215499  0.354
2017 Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold SE, Pienta KJ, Pomper MG. Low level endogenous prostate-specific membrane antigen (PSMA) expression in non-prostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025989 DOI: 10.2967/Jnumed.117.191221  0.32
2017 Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl M, Lapa C. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025983 DOI: 10.2967/Jnumed.117.199778  0.333
2017 Rowe S, Johnson P, Fishman E. Initial Experience with Cinematic Rendering for Chest Cardiovascular Imaging. The British Journal of Radiology. 20170558. PMID 28936892 DOI: 10.1259/Bjr.20170558  0.313
2017 Rowe S, Pienta K, Pomper MG, Gorin M. Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28887401 DOI: 10.2967/Jnumed.117.195255  0.321
2017 Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, Schwarzenboeck SM, Kratowchil C, Herrmann K, Giesel FL. Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 58: 67S-76S. PMID 28864615 DOI: 10.2967/Jnumed.116.186767  0.375
2017 Joice GA, Rowe SP, Pienta KJ, Gorin MA. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology. Current Opinion in Urology. PMID 28863016 DOI: 10.1097/Mou.0000000000000449  0.327
2017 Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine. PMID 28831739 DOI: 10.1007/S12149-017-1201-4  0.353
2017 Rowe SP, Gorin MA, Chu LC, Pienta KJ, Pomper MG, Ross AE, Macura KJ. An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine. PMID 28806262 DOI: 10.1097/Rlu.0000000000001785  0.376
2017 Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28765998 DOI: 10.1007/S00259-017-3780-7  0.384
2017 Salas Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ, Solnes LB, Javadi MS, Szabo Z, Pomper MG, Rowe SP. Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. Clinical Nuclear Medicine. PMID 28737579 DOI: 10.1097/Rlu.0000000000001769  0.373
2017 Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, et al. PSMA-targeted (18)F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study. The Journal of Urology. PMID 28736318 DOI: 10.1016/J.Juro.2017.07.070  0.362
2017 Gorin MA, Pomper MG, Pienta KJ, Rowe SP. Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer. Bju International. 120: 160-161. PMID 28719112 DOI: 10.1111/Bju.13801  0.373
2017 Gorin MA, Mareshdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Nuclear Medicine Communications. PMID 28704341 DOI: 10.1097/Mnm.0000000000000716  0.382
2017 Schwarzenböck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Afshar-Oromieh A, Herrmann K, Eiber M. PSMA Ligands for PET-Imaging of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28687599 DOI: 10.2967/Jnumed.117.191031  0.385
2017 Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). Bmc Cancer. 17: 453. PMID 28662647 DOI: 10.1186/s12885-017-3455-6  0.339
2017 Gorin MA, Pienta KJ, Pomper MG, Rowe SP. Prostate Cancer Local Recurrence Detected with Both (18)F-Fluciclovine and PSMA-Targeted (18)F-DCFPyL PET/CT. Urology. PMID 28641974 DOI: 10.1016/J.Urology.2017.06.015  0.383
2017 Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL. Pet Clinics. 12: 289-296. PMID 28576167 DOI: 10.1016/J.Cpet.2017.02.006  0.381
2017 Cho SY, Lipson EJ, Im HJ, Rowe SP, Mena E, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early Time-Point FDG-PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28360208 DOI: 10.2967/Jnumed.116.188839  0.324
2017 Rowe SP, Gorin MA, Salas Fragomeni RA, Drzezga A, Pomper MG. Clinical Experience with (18)F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. Pet Clinics. 12: 235-241. PMID 28267456 DOI: 10.1016/J.Cpet.2016.12.006  0.388
2017 Gorin MA, Rowe SP, Denmeade SR. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. Pet Clinics. 12: 185-192. PMID 28267452 DOI: 10.1016/J.Cpet.2016.11.001  0.358
2017 Solnes LB, Jones KM, Rowe SP, Pattanayak P, Nalluri A, Venkatesan A, Probasco JC, Javadi MS. Diagnostic Value of (18)F-FDG PET/CT versus MRI in the Setting of Antibody Specific Autoimmune Encephalitis. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28209905 DOI: 10.2967/Jnumed.116.184333  0.34
2017 Phillips R, Gorin M, Rowe S, Hayman J, Radwan N, Pomper M, Allaf M, Eisenberger M, Ross A, Pienta K, DeWeese T, Greco S, Song D, Deville C, Tran P. Changes in Radiotherapeutic Management of Prostate Cancer Following PSMA-based 18 F-DCFPyL PET Imaging: A Snapshot of Prospective Trials at a Single Institution International Journal of Radiation Oncology*Biology*Physics. 99: E259-E260. DOI: 10.1016/J.Ijrobp.2017.06.1224  0.349
2016 Sheikhbahaei S, Marcus C, Fragomeni RS, Rowe SP, Javadi MS, Solnes LB. Whole Body FDG-PET and FDG-PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic review and Meta-analysis of Diagnostic Accuracy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27980049 DOI: 10.2967/Jnumed.116.183905  0.324
2016 Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG. Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27932557 DOI: 10.2967/Jnumed.116.179739  0.384
2016 Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE. Correlation of PSMA-Targeted (18)F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. PMID 27751686 DOI: 10.1016/J.Clgc.2016.09.002  0.37
2016 Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, Pomper MG. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 90S-96S. PMID 27694179 DOI: 10.2967/Jnumed.115.170175  0.384
2016 Solnes LB, Javadi MS, Rowe SP. 18F-FDG PET/CT Imaging of Cauda Equina Syndrome Secondary to Leptomeningeal Metastatic Breast Cancer. Clinical Nuclear Medicine. PMID 27607169 DOI: 10.1097/Rlu.0000000000001354  0.32
2016 Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, Banerjee SR, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, et al. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget. PMID 27437764 DOI: 10.18632/Oncotarget.10602  0.303
2016 Salas Fragomeni RA, Rowe SP. Intense 18F-FDG Uptake in Chronic Subcutaneous Opioid Injection Sites. Clinical Nuclear Medicine. PMID 27405027 DOI: 10.1097/Rlu.0000000000001292  0.312
2016 Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, Pomper MG, Allaf ME. PSMA-Targeted (18)F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. European Urology. PMID 27363386 DOI: 10.1016/J.Eururo.2016.06.019  0.349
2016 Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer and Prostatic Diseases. PMID 27136743 DOI: 10.1038/Pcan.2016.13  0.372
2016 Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27080322 DOI: 10.1007/S11307-016-0957-6  0.393
2016 Gorin MA, Pomper MG, Rowe SP. PSMA-targeted imaging of prostate cancer: the best is yet to come. Bju International. 117: 715-6. PMID 27079480 DOI: 10.1111/Bju.13435  0.337
2016 Wakabayashi H, Werner RA, Hayakawa N, Javadi MS, Chen X, Herrman K, Rowe SP, Lapa C, Higuchi T. Initial Preclinical Evaluation of 18F-fluorodeoxysorbitol PET as a Novel Functional Renal Imaging Agent. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27013700 DOI: 10.2967/Jnumed.116.172718  0.318
2016 Rowe SP, Hawasli H, Fishman EK, Johnson PT. Advances in the Treatment of Oligometastatic Disease:: What the Radiologist Needs to Know to Guide Patient Management. Academic Radiology. PMID 26781202 DOI: 10.1016/J.Acra.2015.11.006  0.302
2016 Gorin MA, Rowe SP, Mana-ay M, Szabo Z, Schaeffer EM, Tran PT, Allaf ME, Deville C, Cho SY, Pienta KJ, Pomper MG, Ross A. Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy. Journal of Clinical Oncology. 34: 299-299. DOI: 10.1200/Jco.2016.34.2_Suppl.299  0.389
2016 Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn H, Wang Y, Ray S, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, et al. Abstract 4206: A dual-motif CAIX inhibitor, [64Cu]XYIMSR-06, for PET imaging of clear cell renal cell carcinoma Cancer Research. 76: 4206-4206. DOI: 10.1158/1538-7445.Am2016-4206  0.306
2016 Gorin MA, Rowe SP, Mana-ay M, Szabo Z, Schaeffer EM, Tran PT, Allaf ME, Deville C, Bivalacqua TJ, Cho SY, Pomper MG, Ross AE. MP50-18 STUDY OF PSMA-TARGETED 18 F-DCFPYL PET/CT IN THE EVALUATION OF MEN WITH AN ELEVATED PSA FOLLOWING RADICAL PROSTATECTOMY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.452  0.35
2016 Gorin MA, Rowe SP, Hooper JE, Hammers H, Kates M, Javadi MS, Hawasli H, Szabo Z, Pomper MG, Allaf ME. MP03-10 PILOT STUDY EVALUATING PSMA-TARGETED 18 F-DCFPYL PET/CT IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1903  0.336
2015 Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, Gorin MA. PSMA-Based Detection of Prostate Cancer Bone Lesions With (18)F-DCFPyL PET/CT: A Sensitive Alternative to (99m)Tc-MDP Bone Scan and Na(18)F PET/CT? Clinical Genitourinary Cancer. PMID 26603549 DOI: 10.1016/J.Clgc.2015.09.011  0.395
2015 Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, et al. Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26493203 DOI: 10.2967/Jnumed.115.163782  0.358
2015 Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT Occult Lesions with 18F-DCFPyL PET/CT in a Patient with Metastatic Renal Cell Carcinoma. Clinical Nuclear Medicine. PMID 26402128 DOI: 10.1097/Rlu.0000000000000995  0.368
2015 Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, Pavlovich CP, Epstein JI, Javadi MS, Allaf ME. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology. PMID 26386607 DOI: 10.1016/J.Eururo.2015.08.056  0.308
2015 Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (18)F-DCFPyL PET/CT. Annals of Nuclear Medicine. PMID 26286635 DOI: 10.1007/S12149-015-1017-Z  0.361
2015 Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, et al. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1003-10. PMID 26069305 DOI: 10.2967/Jnumed.115.154336  0.359
2015 Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 565-74. PMID 25896814 DOI: 10.1007/S11307-015-0850-8  0.358
2015 Rowe SP, Gorin MA, Gordetsky J, Ball MW, Pierorazio PM, Higuchi T, Epstein JI, Allaf ME, Javadi MS. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clinical Nuclear Medicine. 40: 309-13. PMID 25608174 DOI: 10.1097/Rlu.0000000000000670  0.302
2014 Rowe SP, Cho SY. The role of PET in the evaluation of musculoskeletal infections. Seminars in Musculoskeletal Radiology. 18: 166-74. PMID 24715448 DOI: 10.1055/S-0034-1371018  0.311
2012 Majmudar CY, Højfeldt JW, Arevang CJ, Pomerantz WC, Gagnon JK, Schultz PJ, Cesa LC, Doss CH, Rowe SP, Vásquez V, Tamayo-Castillo G, Cierpicki T, Brooks CL, Sherman DH, Mapp AK. Sekikaic acid and lobaric acid target a dynamic interface of the coactivator CBP/p300. Angewandte Chemie (International Ed. in English). 51: 11258-62. PMID 23042634 DOI: 10.1002/Anie.201206815  0.735
2009 Buhrlage SJ, Bates CA, Rowe SP, Minter AR, Brennan BB, Majmudar CY, Wemmer DE, Al-Hashimi H, Mapp AK. Amphipathic small molecules mimic the binding mode and function of endogenous transcription factors. Acs Chemical Biology. 4: 335-44. PMID 19348463 DOI: 10.1021/Cb900028J  0.717
2008 Rowe SP, Mapp AK. Assessing the permissiveness of transcriptional activator binding sites. Biopolymers. 89: 578-81. PMID 18253946 DOI: 10.1002/Bip.20946  0.649
2007 Rowe SP, Casey RJ, Brennan BB, Buhrlage SJ, Mapp AK. Transcriptional up-regulation in cells mediated by a small molecule. Journal of the American Chemical Society. 129: 10654-5. PMID 17691790 DOI: 10.1021/Ja0736865  0.761
2005 Lu Z, Rowe SP, Brennan BB, Davis SE, Metzler RE, Nau JJ, Majmudar CY, Mapp AK, Ansari AZ. Unraveling the mechanism of a potent transcriptional activator. The Journal of Biological Chemistry. 280: 29689-98. PMID 15886204 DOI: 10.1074/Jbc.M504895200  0.767
2003 Wu Z, Belanger G, Brennan BB, Lum JK, Minter AR, Rowe SP, Plachetka A, Majmudar CY, Mapp AK. Targeting the transcriptional machinery with unique artificial transcriptional activators. Journal of the American Chemical Society. 125: 12390-1. PMID 14531665 DOI: 10.1021/Ja036685V  0.726
Show low-probability matches.